[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 6 sources · 5 days · First seen · Last updated

South Korean bio-healthcare KOSDAQ listings

Overview

The South Korean bio-healthcare sector is seeing significant activity regarding KOSDAQ listings and investment returns.

Mint Venture Partners reported substantial returns from its ‘Mint Global Biotech Private Equity Partnership’ fund following the KOSDAQ listings of three portfolio companies: AimedBio, Mezoo, and OrganoidScience. The firm, which utilizes a venture studio model to nurture startups from universities and hospitals, intends to expand into AI healthcare and precision medicine through new funds.

In a related development, MS Bio, a regenerative medicine company specializing in human tissue and biomaterials, has filed a securities report to begin its own KOSDAQ listing process. The company aims to complete the listing in October, using the proceeds to build a new factory in Ochang, establish international bases in the US and Vietnam, and fund clinical trials.

Entities

Kim Seong-po · Financial Services Commission · MS Bio · KB Securities

Timeline

  1. 7 days ago

    [BUSINESS] 4 sources
    MS Bio files for KOSDAQ listing to expand regenerative medicine platform

    MS Bio has filed for a KOSDAQ listing, aiming to raise up to 31.2 billion KRW through a 4-million-share offering to expand its regenerative medicine platform and global production capabilities.

  2. 11 days ago

    [BUSINESS] 2 sources
    Mint Venture Partners sees major returns as three portfolio companies list on KOSDAQ

    Mint Venture Partners achieved major returns, including a 23.1x exit from AimedBio, as three of its bio-healthcare portfolio companies successfully listed on the KOSDAQ.

Sources

biotimes.co.kr · kormedi.com · newstomato.com · thebionews.net · tokenpost.kr · zdnet.co.kr